Business Wire

IL-GE-TRANSPORTATION

18.9.2018 08:02:12 CEST | Business Wire | Press release

Share
GE Transportation Announces New High-Speed Engine Program

GE Transportation (NYSE:GE) announced today at InnoTrans 2018 a new high-speed diesel engine program, which will serve the locomotive, marine and power generation segments. The engine platform will provide improved fuel efficiency and reliability, as well as lower lifecycle costs.

“This new, high-speed engine will be a game changer for our customers,” said Dominique Malenfant, Vice President of Global Technology for GE Transportation. “They will enjoy reduced operating costs and increased availability with this engine. It will generate annual savings for customers of up to $12,000 in diesel and $4,000 in services.”

Compared to similarly sized locomotive engines, GE Transportation’s high-speed engine will offer a 5 percent better total cost of ownership. It will be 5 percent more fuel efficient, saving customers more than 6,000 gallons of diesel per year. The engine also will reduce maintenance costs by 10 percent and provide 184-day service intervals. Overhauls will be on 10-year intervals.

“We are leveraging our expertise and technology in the medium-speed engine segment to create a smaller, power-dense engine platform for products such as shunters and light-weight locomotives,” said Malenfant. “This new program will open up new segments for our business.”

The combination of a powerful engine at a smaller size and weight makes the platform ideal in regions like Asia, Africa, South America, Australia and New Zealand, which require lighter locomotives. Kazakhstan Temir Zholy (KTZ) will be the first to use the new engine to power the 300 shunter locomotives ordered earlier this year. GE Transportation will deliver the first shunter to KTZ in 2019.

“GE technology is the primary driver for developing Kazakhstan’s rail industry,” said Kanat Alpysbayev, Chairman of KTZ. “The high-speed engine will provide our new shunter fleet with the performance and maintainability needed to conduct our operations in a cost-effective manner.”

GE Transportation is developing the platform for application in multiple segments. The company is designing the high-speed diesel engine in 12- and 16-cylinder configurations with a maximum-rated horsepower of 2,500 and 3,300 respectively. At 7.40 lbs. per horsepower, the design will be 40 percent more powerful per pound compared to a medium-speed engine. It also will be digitally ready with remote prognostic capabilities to improve performance and reliability. Additionally, the engine design will meet the emission standards for both the European Union’s Stage III A/B and the International Union of Railways’ UIC Stage I/II.

The core architecture of the engine platform was jointly developed with GE Distributed Power, incorporating decades of high-speed engine experience across the Jenbacher and Waukesha product lines. GE Distributed Power is targeting a serialization of the technology to introduce a range of stationary gas engine operating potentially as soon as 2020.

Visit the GE Transportation InnoTrans 2018 webpage to learn more about this week’s announcements, demos and displays. The GE Transportation booth is located at Hall 3.2, Stand 401.

About GE Transportation

At GE Transportation , we move the world and improve the world. We are a global technology leader and supplier of equipment, services and digital solutions to the rail, mining, marine, stationary power and drilling industries. Our innovations help customers deliver goods and services with greater speed and savings using our advanced manufacturing techniques and connected machines. GE Transportation is headquartered in Chicago, IL, and employs approximately 9,000 employees worldwide.

Contact:

GE Transportation Deia Campanelli 773-297-0482 deia.campanelli@ge.com

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release

REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release

In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release

- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c

Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release

Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til

IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release

Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye